EXTH-71. HYPERPOLARIZED [1-13C] PYRUVATE AS A BIOMARKER FOR TREATMENT MONITORING IN LYMPHOMA MURINE MODELS. Read more about EXTH-71. HYPERPOLARIZED [1-13C] PYRUVATE AS A BIOMARKER FOR TREATMENT MONITORING IN LYMPHOMA MURINE MODELS.
IMMU-52. SELECTION OF GLIOMA T-CELL THERAPY TARGETS BASED ON THE ANALYSIS OF TUMOR IMMUNOPEPTIDOME AND EXPRESSION PROFILES. Read more about IMMU-52. SELECTION OF GLIOMA T-CELL THERAPY TARGETS BASED ON THE ANALYSIS OF TUMOR IMMUNOPEPTIDOME AND EXPRESSION PROFILES.
EXTH-23. ANTISECRETORY FACTOR-MEDIATED LOWERING OF INTERSTITIAL FLUID PRESSURE PRODUCES ANTI-TUMOR ACTIVITY IN GLIOBLASTOMA. Read more about EXTH-23. ANTISECRETORY FACTOR-MEDIATED LOWERING OF INTERSTITIAL FLUID PRESSURE PRODUCES ANTI-TUMOR ACTIVITY IN GLIOBLASTOMA.
GENE-33. THE 3D EVOLUTION AND IN VIVO GROWTH PATTERNS OF GLIOMA CELL POPULATIONS. Read more about GENE-33. THE 3D EVOLUTION AND IN VIVO GROWTH PATTERNS OF GLIOMA CELL POPULATIONS.
EXTH-55. REPURPOSING THERAPEUTICS IN PATIENT-DERIVED GLIOMAS AND AN IDH1 MUTANT GLIOMA MODEL. Read more about EXTH-55. REPURPOSING THERAPEUTICS IN PATIENT-DERIVED GLIOMAS AND AN IDH1 MUTANT GLIOMA MODEL.
A phase I trial of the MEK inhibitor selumetinib (AZD6244) in pediatric patients with recurrent or refractory low-grade glioma: a Pediatric Brain Tumor Consortium (PBTC) study. Read more about A phase I trial of the MEK inhibitor selumetinib (AZD6244) in pediatric patients with recurrent or refractory low-grade glioma: a Pediatric Brain Tumor Consortium (PBTC) study.
Toca 511 gene transfer and treatment with the prodrug, 5-fluorocytosine, promotes durable antitumor immunity in a mouse glioma model. Read more about Toca 511 gene transfer and treatment with the prodrug, 5-fluorocytosine, promotes durable antitumor immunity in a mouse glioma model.
Retroviral replicating vector-mediated gene therapy achieves long-term control of tumor recurrence and leads to durable anticancer immunity. Read more about Retroviral replicating vector-mediated gene therapy achieves long-term control of tumor recurrence and leads to durable anticancer immunity.
Is the immune response a friend or foe for viral therapy of glioma? Read more about Is the immune response a friend or foe for viral therapy of glioma?
DIPG-16. NONINVASIVE ASSESSMENT OF TREATMENT RESPONSE FOR DIFFUSE INTRINSIC PONTINE GLIOMA USING HYPERPOLARIZED 13C METABOLIC IMAGING. Read more about DIPG-16. NONINVASIVE ASSESSMENT OF TREATMENT RESPONSE FOR DIFFUSE INTRINSIC PONTINE GLIOMA USING HYPERPOLARIZED 13C METABOLIC IMAGING.
